US 11,702,431 B2
Oxo-substituted compound
Toshio Kanai, Osaka (JP); Sachiko Koike, Osaka (JP); Takayuki Fukaya, Osaka (JP); Shunichiro Uesugi, Osaka (JP); Shingo Mizushima, Osaka (JP); Hitoshi Suda, Osaka (JP); Yuki Mizukami, Osaka (JP); Yohei Ikuma, Osaka (JP); Toshiaki Sunazuka, Minato-ku (JP); and Yoshihiko Noguchi, Minato-ku (JP)
Assigned to Sumitomo Pharma Co., Ltd., Osaka (JP); and THE KITASATO INSTITUTE, Minato-ku (JP)
Appl. No. 17/50,747
Filed by Sumitomo Pharma Co., Ltd., Osaka (JP); and THE KITASATO INSTITUTE, Minato-ku (JP)
PCT Filed Apr. 26, 2019, PCT No. PCT/JP2019/018011
§ 371(c)(1), (2) Date Oct. 26, 2020,
PCT Pub. No. WO2019/208797, PCT Pub. Date Oct. 31, 2019.
Claims priority of application No. JP2018-087761 (JP), filed on Apr. 27, 2018.
Prior Publication US 2021/0147448 A1, May 20, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07F 5/02 (2006.01); A61P 31/04 (2006.01); A61K 45/06 (2006.01); A61K 31/407 (2006.01); A61K 31/69 (2006.01)
CPC C07F 5/025 (2013.01) [A61K 31/407 (2013.01); A61K 31/69 (2013.01); A61K 45/06 (2013.01); A61P 31/04 (2018.01)] 68 Claims
 
1. A compound represented by formula (5a) or (5b):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof,
wherein
Y is an oxygen atom,
ring A is an optionally substituted 4- to 20-membered non-aryl heterocycle,
L3 is —C(═O)—,
L4 is
1) a single bond,
2) a C1-6 alkylene group,
3) a C3-10 cycloalkylene group,
4) a C6-10 arylene group,
5) a 5- or 6-membered heteroarylene group,
6) a 4- to 10-membered non-aryl heterocyclylene group, or
7) —C(═N—ORh1)—,
8) —CD(NH2)— wherein D represents a heavy hydrogen atom
wherein each substituent from 2) to 6) is optionally substituted, and
R5 is
1) a hydrogen atom,
2) a C1-6 alkyl group,
3) a C3-10 alicyclic group,
4) a 4- to 10-membered non-aryl heterocycle,
5) C6-10 aryl,
6) 5- or 6-membered heteroaryl,
7) a C1-6 alkylthio group,
wherein each substituent from 2) to 7) is optionally substituted, or
8) —NRe1OH,
R1 and R2 are the same or different, each independently a hydrogen atom, a halogen atom, an optionally substituted C1-6 alkyl group, an optionally substituted C1-6 alkoxy group, an optionally substituted C1-6 alkylthio group, an optionally substituted 5- or 6-membered heteroaryl, or —NRa3Rb2,
Re1 and are the same or different, each independently a hydrogen atom, an optionally substituted C1-6 alkyl group, an optionally substituted C3-10 alicyclic group, optionally substituted C6-10 aryl, optionally substituted 5- or 6-membered heteroaryl, or an optionally substituted 4- to 10-membered non-aryl heterocycle,
Ra3 and are the same or different, each independently
1) a hydrogen atom,
2) a C1-6 alkyl group,
3) a C3-10 alicyclic group,
4) C6-10 aryl
5) 5- or 6-membered heteroaryl,
6) a 4- to 10-membered non-aryl heterocycle,
7) a C1-6 alkylcarbonyl group,
8) a C3-10 alicyclic carbonyl group,
9) a C6-10 arylcarbonyl group,
10) a 5- or 6-membered heteroarylcarbonyl group,
11) a C4-6 alkysulfonyl group,
12) a C3-10 alicyclic sulfonyl group,
13) a C6-10 arylsulfonyl group,
14) a 5- or 6-membered heteroarylsulfonyl group, or
15) —ORc1,
wherein each substituent from 2) to 14) is optionally substituted,
Rc1 is
1) a hydrogen atom,
2) a C1-6 alkyl group,
3) a C3-10 alicyclic group,
4) C6-10 aryl,
5) 5- or 6-membered heteroaryl, or
6) a 4- to 10-membered non-aryl heterocycle,
wherein each substituent from 2) to 6) is optionally substituted,
wherein a combination of Ra3 and Rb2, when attached to the same nitrogen atom, together may form an optionally substituted 4- to 10-membered nitrogen-containing non-aryl heterocycle.